PTPRC and neoplasm: After establishing that this BH treatment regimen controls distal tumor growth (Figure 1), we examined the time course of antigen acquisition by all immune cells, as identified by CD45+ staining, in the TDLNs in a unilateral B16F10-ZsG model in response to BH (Figure 2A).